Investigator-Initiated Research Award – HT942526RTRPIIRA
- letters of intent due 21 October 2026
- up to USD$1M over 3 years
- supports studies that have the potential to make an important contribution to reconstructive transplant research, patient care and/or quality of life.
- projects may focus on any phase of research from basic through translational
- preliminary/ published data required
- pre-clinical studies in animal models allowed
- clinical research in human subjects or human anatomical substances allowed
- correlative studies associated with an existing clinical trial allowed
- clinical trials not allowed
- allows for the leveraging of novel findings from solid organ transplant research for testing in a VCA setting, so long as the rationale and benefits for doing so are appropriately explained and justified
- must address at least one of the focus areas
- improve or optimise vascularized composite allotransplantation (VCA) immunosuppression
- identify and/or validate reliable prognostic or diagnostic biomarkers, methods or tools for monitoring the specific needs of VCA graft rejection and immunosuppression
- advance VCA preservation strategies
- develop tools for measuring VCA outcomes
- Apply here
- Document – Program Announcement – HT942526RTRPIIRA_GG
